Arctiin is a pharmacological inhibitor of STAT3 phosphorylation at tyrosine 705 residue and potentiates bortezomib-induced apoptotic and anti-angiogenic effects in human multiple myeloma cells

Phytomedicine. 2019 Mar 1:55:282-292. doi: 10.1016/j.phymed.2018.06.038. Epub 2018 Aug 11.

Abstract

Background: Arctiin is a main component from the fruits of Arctium lappa L., that can be prescribed for cold or flu in East Asian countries; it has also been found to exert chemopreventive actions against various tumor cells.

Hypothesis: In view of this evidence, we examined arctiin for its ability to trigger apoptosis and inhibit the activation of signal transducer and activator of transcription 3 (STAT3) in human multiple myeloma (MM) cells.

Methods: We evaluated the effect of arctiin on STAT3 signaling cascades and its regulated functional responses in MM cells.

Results: Arctiin effectively blocked the constitutive activation of STAT3 phosphorylation in the residue of tyrosine 705. Arctiin also abrogated the constitutive activation of Src phosphorylation and Janus-activated kinases (JAKs) 1/2. Furthermore, it was found that arctiin treatment clearly enhanced the mRNA and protein levels of protein tyrosine phosphatase ε (PTPε), and the silencing of PTPε caused a reversal of the arctiin-induced PTPε expression and the blockadge of STAT3 phosphorylation. Interestingly, arctiin could not repress IL-6-induced STAT3 activation in serum-starved U266 cells and when arctiin was incubated with a complete culture medium in RPMI 8226 and MM.1S cells. Arctiin suppressed cell proliferation, accumulated cells in the G2/M cell-cycle phase, and induced apoptosis within U266 cells, although the knockdown of PTPε prevented PARP cleavage and caspase-3 activation induced by the arctiin. In addition, arctiin exerted cytotoxicity in MM cells, but did not do so in peripheral blood mononuclear cells. Arctiin down-modulated diverse oncogenic gene products regulated by STAT3, although the induction of apoptosis by arctiin was abrogated upon transfection with pMXs-STAT3C in mouse embryonic fibroblast (MEF) cells. Arctiin also potentiated bortezomib-induced antitumor effects in U266 cells.

Conclusion: On the whole, our results indicate that arctiin is a potentially new inhibitor of constitutive STAT3 activation through the induction of PTPε in MM, cells and therefore has great value in treating various tumors sheltering constitutively activated STAT3.

Keywords: Apoptosis; Arctiin; MM; PTPε; STAT3.

MeSH terms

  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Apoptosis / drug effects*
  • Arctium / chemistry
  • Bortezomib / adverse effects
  • Cell Line, Tumor / drug effects
  • Cell Proliferation / drug effects*
  • Drugs, Chinese Herbal / pharmacology
  • Drugs, Chinese Herbal / therapeutic use
  • Furans / pharmacology*
  • Furans / therapeutic use*
  • Glucosides / pharmacology*
  • Glucosides / therapeutic use*
  • Humans
  • Multiple Myeloma / drug therapy*
  • Phosphorylation / drug effects*
  • Plant Extracts / pharmacology
  • Plant Extracts / therapeutic use
  • Receptor-Like Protein Tyrosine Phosphatases, Class 4 / drug effects
  • STAT3 Transcription Factor / drug effects
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction / drug effects
  • Tyrosine / drug effects*

Substances

  • Angiogenesis Inhibitors
  • Drugs, Chinese Herbal
  • Furans
  • Glucosides
  • Plant Extracts
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Tyrosine
  • Bortezomib
  • Receptor-Like Protein Tyrosine Phosphatases, Class 4
  • arctiin